Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Non-Hodgkin lymphoma, adult
Results 1-25 of 464 for your search:
Start Over
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: 3066K1-4438, NCI-2014-00131, 2009-015498-11, B1771007, NCT01180049
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
Phase: Phase III, Phase II
Type: Supportive care
Age: 18 months to 21 years
Trial IDs: #1R01FD003410-01, NCI-2014-01209, R01 FD003410-01-A1, NCT00999713
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 113676, NCI-2012-01195, NCT01200589
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Double Cord Versus Haploidentical (BMT CTN 1101)
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: BMTCTN1101, NCI-2014-00307, 2U10HL069294-11, 715, NCT01597778
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-313-0124, NCI-2013-01738, NCT01732913
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116428, NCI-2014-01414, 2012-003438-18, NCT01767467
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR100955, NCI-2013-02262, 2012-004225-24, PCI-32765CAN3001, NCT01804686
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Age: 65 and under
Trial IDs: CB-AB006, NCI-2013-00758, 2012-0166, NCT01854567
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-5013-NHL-007, NCI-2014-02022, NCT01938001
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-5013-NHL-008, NCI-2015-00708, NCT01996865
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-07, NCI-2014-00977, NCT02004522
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: E1912, NCI-2014-00118, ECOG-E1912, NCT02048813
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-12, NCI-2014-02041, NCT02049515
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1127-CA, NCI-2014-01363, NCT02165397
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IPI-145-08, NCI-2015-00134, 2013-002406-31, NCT02204982
Start Over